Apellis Pharmaceuticals (APLS) Short Interest Ratio & Short Volume $24.49 +0.23 (+0.94%) As of 01:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Apellis Pharmaceuticals Short Interest DataApellis Pharmaceuticals (APLS) has a short interest of 16.49 million shares. This marks a -36.94% decrease in short interest from the previous month. The short interest ratio (days to cover) is 6.9, indicating that it would take 6.9 days of the average trading volume of 2.28 million shares to cover all short positions.Current Short Interest16,490,000 sharesPrevious Short Interest26,150,000 sharesChange Vs. Previous Month-36.94%Dollar Volume Sold Short$319.08 millionShort Interest Ratio6.9 Days to CoverLast Record DateJuly 15, 2025Outstanding Shares126,290,000 sharesPercentage of Shares Shorted13.06%Today's Trading Volume1,128,335 sharesAverage Trading Volume2,282,721 sharesToday's Volume Vs. Average49% Short Selling Apellis Pharmaceuticals? Sign up to receive the latest short interest report for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartAPLS Short Interest Over TimeAPLS Days to Cover Over TimeAPLS Percentage of Float Shorted Over Time Apellis Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/15/202516,490,000 shares $319.08 million -36.9%N/A6.9 $19.35 6/30/202526,150,000 shares $452.66 million +4.0%22.3%10.5 $17.31 6/15/202525,140,000 shares $473.39 million +0.4%21.4%9.7 $18.83 5/31/202525,030,000 shares $423.26 million -8.2%21.6%9.7 $16.91 5/15/202527,250,000 shares $445.81 million -5.3%23.5%11 $16.36 4/30/202528,770,000 shares $552.67 million +7.2%N/A12.6 $19.21 4/15/202526,830,000 shares $508.97 million +19.2%23.1%13.4 $18.97 3/31/202522,510,000 shares $492.29 million +16.6%19.4%11.4 $21.87 3/15/202519,310,000 shares $476.18 million -7.3%16.7%11 $24.66 2/28/202520,820,000 shares $523.62 million +20.1%18.0%10.5 $25.15 Get the Latest News and Ratings for APLS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 2/15/202517,340,000 shares $475.12 million +1.6%15.0%8 $27.40 1/31/202517,060,000 shares $494.91 million -5.4%N/A6.5 $29.01 1/15/202518,040,000 shares $523.70 million -16.0%N/A6 $29.03 12/31/202421,480,000 shares $685.43 million +7.4%N/A6.9 $31.91 12/15/202420,010,000 shares $664.13 million -8.3%N/A6 $33.19 11/30/202421,810,000 shares $740.01 million -5.9%N/A6.7 $33.93 11/15/202423,180,000 shares $608.94 million +11.5%N/A7.7 $26.27 10/31/202420,790,000 shares $566.74 million -1.4%N/A8.7 $27.26 10/15/202421,090,000 shares $589.47 million +38.2%N/A9.9 $27.95 9/30/202415,260,000 shares $440.10 million -0.1%N/A7.9 $28.84 9/15/202415,280,000 shares $574.83 million -5.5%N/A9.6 $37.62 8/31/202416,170,000 shares $629.01 million -0.6%N/A11.2 $38.90 8/15/202416,270,000 shares $612.08 million +2.2%N/A11.2 $37.62 7/31/202415,920,000 shares $630.43 million +4.9%N/A10.6 $39.60 7/15/202415,170,000 shares $606.80 million +2.4%N/A10.3 $40.00 6/30/202414,810,000 shares $568.11 million +6.6%N/A10.1 $38.36 6/15/202413,900,000 shares $583.80 million +6.0%N/A10.1 $42.00 5/31/202413,120,000 shares $514.96 million +4.2%N/A9.6 $39.25 5/15/202412,590,000 shares $527.77 million +1.6%N/A8.6 $41.92 4/30/202412,390,000 shares $547.51 million +16.1%N/A8.4 $44.19 4/15/202410,670,000 shares $549.51 million +2.2%N/A8 $51.50 3/31/202410,440,000 shares $613.66 million -1.4%N/A7.1 $58.78 3/15/202410,590,000 shares $600.88 million +5.3%N/A6.7 $56.74 2/29/202410,060,000 shares $623.42 million -2.0%N/A5.1 $61.97 2/15/202410,270,000 shares $694.05 million -3.8%N/A4.9 $67.58 1/31/202410,670,000 shares $675.30 million -11.3%N/A5.1 $63.29 1/15/202412,030,000 shares $844.87 million +2.9%N/A5.4 $70.23 12/31/202311,690,000 shares $699.76 million -9.9%N/A5.1 $59.86 12/15/202312,980,000 shares $683.79 million -14.9%N/A5.2 $52.68 11/30/202315,260,000 shares $822.06 million -5.5%N/A6.4 $53.87Musk’s Project Colossus could mint millionaires (Ad)I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.All the details are waiting for you now — but you need to act before the September 1st funding windo 11/15/202316,140,000 shares $781.18 million -0.6%N/A6.9 $48.40 10/31/202316,230,000 shares $789.75 million -12.7%N/A5.2 $48.66 10/15/202318,590,000 shares $900.50 million +10.9%N/A4.5 $48.44 9/30/202316,770,000 shares $637.93 million +23.2%N/A3.3 $38.04 9/15/202313,610,000 shares $604.83 million +10.6%N/A2.9 $44.44 8/31/202312,310,000 shares $519.61 million -10.5%N/A2.7 $42.21 8/15/202313,750,000 shares $449.90 million +43.2%N/A3.1 $32.72 7/31/20239,600,000 shares $247.20 million +1.3%N/A2.6 $25.75 7/15/20239,480,000 shares $801.06 million -1.2%N/A3.5 $84.50 6/30/20239,590,000 shares $873.65 million -16.3%N/A6 $91.10 6/15/202311,460,000 shares $1.03 billion +0.9%N/A6.7 $89.60 5/31/202311,360,000 shares $975.26 million +3.3%N/A7 $85.85 5/15/202311,000,000 shares $969.21 million +7.0%N/A5.6 $88.11 4/30/202310,280,000 shares $857.66 million -16.6%N/A5.4 $83.43 4/15/202312,330,000 shares $998.11 million +0.4%N/A6.7 $80.95 3/31/202312,280,000 shares $809.99 million +1.1%N/A7.1 $65.96 3/15/202312,150,000 shares $796.19 million +13.1%N/A7.6 $65.53 2/28/202310,740,000 shares $703.26 million +18.5%N/A7.4 $65.48 2/15/20239,060,000 shares $479.82 million -0.6%N/A6.5 $52.96 1/31/20239,110,000 shares $480.37 million -5.0%N/A6.9 $52.73 1/15/20239,590,000 shares $504.05 million +4.6%N/A7.4 $52.56 12/30/20229,170,000 shares $474.18 million -8.8%N/A7.1 $51.71 12/15/202210,050,000 shares $526.72 million +1.9%N/A6.9 $52.41 11/30/20229,860,000 shares $492.31 million -5.1%N/A6.6 $49.93 11/15/202210,390,000 shares $484.28 million +6.8%N/A6.3 $46.61 10/31/20229,730,000 shares $588.57 million +10.8%N/A6.6 $60.49 10/15/20228,780,000 shares $499.93 million -10.6%N/A6.4 $56.94 9/30/20229,820,000 shares $670.71 million +7.9%N/A6.8 $68.30 9/15/20229,100,000 shares $589.23 million +8.6%N/A6.9 $64.75 8/31/20228,380,000 shares $507.07 million +4.9%N/A6.5 $60.51 8/15/20227,990,000 shares $548.43 million -18.8%N/A7.4 $68.64 7/31/20229,840,000 shares $553.80 million +5.0%N/A8.8 $56.28 7/15/20229,370,000 shares $431.68 million -4.4%N/A8.8 $46.07 6/30/20229,800,000 shares $443.16 million +7.1%N/A9.9 $45.22 6/15/20229,150,000 shares $376.71 million +2.0%N/A8.1 $41.17 5/31/20228,970,000 shares $371.81 million -2.0%N/A7.5 $41.45 5/15/20229,150,000 shares $360.97 million +3.7%N/A7.5 $39.45 4/30/20228,820,000 shares $383.93 million +12.4%N/A7.7 $43.53 4/15/20227,850,000 shares $414.56 million +7.7%N/A6.8 $52.81 3/31/20227,290,000 shares $370.40 million +14.1%N/A6.3 $50.81 3/15/20226,390,000 shares $255.92 million -7.0%8.0%6.8 $40.05 2/28/20226,870,000 shares $292.18 million -1.3%8.5%8.1 $42.53 2/15/20226,960,000 shares $327.61 million -4.7%8.8%8.2 $47.07 1/31/20227,300,000 shares $293.97 million +17.0%9.3%6.8 $40.27 1/15/20226,240,000 shares $251.85 million -6.7%7.9%5.9 $40.36 12/31/20216,690,000 shares $316.30 million -7.3%8.5%6.5 $47.28 12/15/20217,220,000 shares $320.06 million +9.1%9.2%6.3 $44.33 11/30/20216,620,000 shares $278.57 million +12.4%8.6%3.7 $42.08 11/15/20215,890,000 shares $247.85 million -1.0%7.6%3.2 $42.08 10/29/20215,950,000 shares $182.90 million +4.0%8.6%3.6 $30.74Musk’s Project Colossus could mint millionaires (Ad)I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.All the details are waiting for you now — but you need to act before the September 1st funding windo 10/15/20215,720,000 shares $198.08 million -10.2%8.3%3.6 $34.63 9/30/20216,370,000 shares $209.96 million +11.4%9.2%4 $32.96 9/15/20215,720,000 shares $194.02 million +10.6%8.3%3.7 $33.92 8/31/20215,170,000 shares $340.44 million +2.4%7.6%5.8 $65.85 8/13/20215,050,000 shares $290.17 million +2.9%7.5%6.4 $57.46 7/30/20214,910,000 shares $314.19 million -21.2%7.9%5.6 $63.99 7/15/20216,230,000 shares $390.18 million +4.9%10.0%7.1 $62.63 6/30/20215,940,000 shares $375.41 million -0.5%9.5%7 $63.20 6/15/20215,970,000 shares $362.08 million +6.4%9.6%7.7 $60.65 5/28/20215,610,000 shares $315.73 million -18.7%9.0%7.2 $56.28 5/14/20216,900,000 shares $314.92 million -10.6%11.0%8.9 $45.64 4/30/20217,720,000 shares $372.41 million -4.0%N/A12.1 $48.24 4/15/20218,040,000 shares $357.62 million +4.6%N/A12.4 $44.48 3/31/20217,690,000 shares $323.36 million +9.2%N/A11.7 $42.05 3/15/20217,040,000 shares $328.49 million -13.2%N/A10.7 $46.66 2/26/20218,110,000 shares $365.36 million +4.7%12.8%11.8 $45.05 2/12/20217,750,000 shares $366.73 million +1.2%12.4%11 $47.32 1/29/20217,660,000 shares $343.93 million -14.3%12.4%10.6 $44.90 1/15/20218,940,000 shares $479.18 million -1.1%15.1%12.5 $53.60 12/31/20209,040,000 shares $516.46 million +7.1%15.3%13.4 $57.13 12/15/20208,440,000 shares $439.30 million -6.6%14.3%12.3 $52.05 11/30/20209,040,000 shares $426.87 million -9.1%15.3%14.6 $47.22 11/15/20209,940,000 shares $384.98 million -2.5%16.8%16.7 $38.73 10/30/202010,190,000 shares $331.79 million -4.2%17.2%18.1 $32.56 10/15/202010,640,000 shares $376.87 million -2.4%18.0%18.6 $35.42 9/30/202010,900,000 shares $328.85 million +3.8%18.5%16.8 $30.17 9/15/202010,500,000 shares $327.60 million +1.9%17.8%15.5 $31.20 8/31/202010,300,000 shares $317.55 million +0.9%17.5%14 $30.83 8/14/202010,210,000 shares $289.76 million +0.7%17.3%13 $28.38 APLS Short Interest - Frequently Asked Questions What is Apellis Pharmaceuticals' current short interest? Short interest is the volume of Apellis Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of July 15th, investors have sold 16,490,000 shares of APLS short. Learn More on Apellis Pharmaceuticals' current short interest. What is a good short interest ratio for Apellis Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. APLS shares currently have a short interest ratio of 7.0. Learn More on Apellis Pharmaceuticals's short interest ratio. Which institutional investors are shorting Apellis Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Apellis Pharmaceuticals: Jane Street Group LLC, Parallax Volatility Advisers L.P., Caption Management LLC, Walleye Trading LLC, Walleye Capital LLC, and Jefferies Financial Group Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Apellis Pharmaceuticals' short interest increasing or decreasing? Apellis Pharmaceuticals saw a drop in short interest during the month of July. As of July 15th, there was short interest totaling 16,490,000 shares, a drop of 36.9% from the previous total of 26,150,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Apellis Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Apellis Pharmaceuticals: Verona Pharma PLC American Depositary Share (4.77%), BridgeBio Pharma, Inc. (10.26%), Blueprint Medicines Corporation (5.95%), Legend Biotech Corporation Sponsored ADR (4.57%), Roivant Sciences Ltd. (10.56%), Regencell Bioscience Holdings Limited (9.57%), Elanco Animal Health Incorporated (4.75%), Revolution Medicines, Inc. (7.33%), Grifols, S.A. (0.96%), TG Therapeutics, Inc. (15.22%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks. What does it mean to sell short Apellis Pharmaceuticals stock? Short selling APLS is an investing strategy that aims to generate trading profit from Apellis Pharmaceuticals as its price is falling. APLS shares are trading up $1.31 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Apellis Pharmaceuticals? A short squeeze for Apellis Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of APLS, which in turn drives the price of the stock up even further. How often is Apellis Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including APLS, twice per month. The most recent reporting period available is July, 15 2025. More Short Interest Resources from MarketBeat Related Companies VRNA Short Interest Data BBIO Short Interest Data BPMC Short Interest Data LEGN Short Interest Data ROIV Short Interest Data RGC Short Interest Data ELAN Short Interest Data RVMD Short Interest Data GRFS Short Interest Data TGTX Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:APLS) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWall Street Hates This Gold IRA Strategy—Here’s WhyWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
